EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report

Sajjad Hassan, Angela Essa, Lauren Orr, Corina N Schoen, Chester Andrzejewski

Transfusion · 2026

DOI: 10.1111/trf.70318 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Transfusion, 2026. Verfasst von Sajjad Hassan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts, USA. Hauptthemen laut MEDLINE: Fetomaternal Transfusion, Rh Isoimmunization, Rho(D) Immune Globulin, Rh-Hr Blood-Group System. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Massive fetomaternal hemorrhage can lead to significant fetal morbidity or mortality. RhD negative patients require appropriate treatment to prevent alloimmunization in subsequent pregnancies. Few cases with follow‐up into future pregnancies have been reported. Case Report and Results 30‐year‐old gravida 3 para 1 presented at 40 weeks and 2 days gestation for late term evaluation. Ultrasonography identified an intrauterine fetal demise. The patient was O RhD negative and had previously received Rh immunoglobin (RhIG) at 26 weeks of gestation. The patient was induced and delivered a 3,450 gram stillborn fetus. Kleihauer‐Betke testing performed and revealed massive fetomaternal hemorrhage with a result of 5.4–6.0%. The calculated fetomaternal hemorrhage was estimated to be 281.6 mL (approaching the total estimated fetal blood volume of 293 mL). The patient received 3 vials of intramuscular RhIG (300 μg/vial), 2 vials of intravenous RhIG (1,000 μg/vial), and 1 vial of intravenous RhIG (300 μg/vial) for a total RhIG dose of 3,200 μg, over a 3‐day period, with no adverse clinical sequelae. Serological investigations for anti‐D antibodies remained positive until 6 months and were inconclusive at 8 months postpartum. At 10 months postpartum, she was 9 weeks pregnant and no anti‐D antibodies were detected. With this subsequent pregnancy, she was treated with routine RhIG and delivered a healthy RhD positive neonate.

Conclusion

Adequate dosing of RhIG can be achieved to prevent alloimmunization, even in massive fetomaternal hemorrhages. After large doses of RhIG, anti‐D antibodies may persist for several months and do not necessarily indicate maternal alloimmunization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetomaternal TransfusionRh IsoimmunizationRho(D) Immune GlobulinRh-Hr Blood-Group SystemHumansFemalePregnancyAdult

Stichwörter der Autor:innen

massive fetomaternal hemorrhageprevention of maternal RhD alloimmunization

Substanzen

Rho(D) Immune GlobulinRh-Hr Blood-Group System

Autor:innen und Institutionen

  • Department of Pathology, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts, USA.
  • Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts, USA.

Zitieren

APA

Hassan, S., Essa, A., Orr, L., Schoen, C. N., & Andrzejewski, C. (2026). Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report. Transfusion. https://doi.org/10.1111/trf.70318

Vancouver

Hassan S, Essa A, Orr L, Schoen CN, Andrzejewski C. Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report. Transfusion. 2026. doi:10.1111/trf.70318

BibTeX
@article{Hassan2026,
  author = {Hassan, Sajjad and Essa, Angela and Orr, Lauren and Schoen, Corina N and Andrzejewski, Chester},
  title = {Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report},
  journal = {Transfusion},
  year = {2026},
  doi = {10.1111/trf.70318}
}
Kostenlos starten →